Objective:To explore the molecular mechanism of Polygalae Radix - Acori Tatarinowii Rhizoma medicinal pair for depression and Alzheimer disease (AD) with the same treatment through network pharmacology. Methods:Effective components of Polygalae Radix - Acori Tatarinowii Rhizoma medicinal pair were retrieved from TCMSP, TCMID and ETCM databases. The disease targets of depression and AD were retrieved from GeneCards, TTD and CTD databases. Targets of action of drugs on active components were predicted through SwissTargetPrediction, and then the intersection targets of medicinal pair and the diseases were taken. Cytoscape 3.6.1 was used to construct the interaction network of Polygalae Radix - Acori Tatarinowii Rhizoma medicinal pair on "component-common target-disease". The enrichment analysis of GO function and KEGG pathway was carried out with the help of Metascape platform, and molecular docking verification was carried out. Results:Through searching the databases and literature, 78 compounds in Polygalae Radix - Acori Tatarinowii Rhizoma medicinal pair were obtained, corresponding to 41 targets of different diseases with the same treatment. The GO function was mainly concentrated in response to lipopolysaccharide and cellular response to nitrogen compound. The KEGG pathway was mainly concentrated in lipid and atherosclerosis, calcium signaling pathway, serotonergic synapse, insulin resistance and so on. The core targets were PTGS2, ESR2, etc. Molecular docking showed that most of the core components could form stable conformation with the core targets. Conclusions:Polygalae Radix - Acori Tatarinowii Rhizoma medicinal pair has the characteristics of multi-component, multi-target and multi-pathway in the same treatment of depression and AD. Through their core components of senegenin, 1-carbobutoxy-β-carboline, 6-hydroxy-1,2,3,7-tetramethoxyxanthone, kaempferol and etc., the pair can act on PTGS2 and other targets, regulate lipid and atherosclerosis, calcium signaling pathway, serotonergic synapse, insulin resistance and so on, and play a therapeutic role in depression and Alzheimer's disease with the same treatment.

Objective:To establish an HPLC fingerprint of Shenling Baizhu Powder and Shenling Baizhu Pills; To evaluate the quality consistency of commercial Shenling Baizhu Powder and Shenling Baizhu Pills.Methods:HPLC method was adopted with Agilent TC-C18 column (250 mm×4.6 mm, 5 μm). The mobile phase was 0.05% phosphoric acid-acetonitrile with gradient elution; the flow rate was 1.0 ml/min; the detection wavelength was 203 nm; the column temperature was 25 ℃. The HPLC fingerprints of Shenling Baizhu Powder and Shenling Baizhu Pills from different manufacturing enterprises were established and analyzed by using the Similarity Evaluation System of Chromatographic Fingerprint of TCM (Version 2012) software for similarity evaluation, and the main chromatographic peaks were identified.Results:The control fingerprints of Shenling Baizhu Powder and Shenling Baizhu Pills were obtained. 73 common peaks and 79 common peaks were identified respectively. The similar degrees of all samples were over 0.92. The quality consistency of drugs different batches of different production enterprises was good. A total of 10 components were identified, including Liquiritin, Ginsenoside Rg1, Ginsenoside Rb1, Glycyrrhizin, Isoliquiritin, Ginsenoside Rd, Glycyrrhizic acid, AtractylenolideⅠ, AtractylenolideⅡ and AtractylenolideⅢ.Conclusions:The established HPLC fingerprints can quickly evaluate the formulation quality of Shenling Baizhu Powder and Shenling Baizhu Pills, providing basis the quality control.